Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. It is grouped under the following drug class(es): Carbohydrates. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Butyldeoxynojirimycin, Zavesca and Yargesa. Its PubChem CID is 51634.
Miglustat
| CAS No | 72599-27-0 |
|---|---|
| Molecular Formula | C10H21NO4 |
| Molecular Weight | 219.28 g/mol |
| Synonyms | (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids.
The listed CAS number is 72599-27-0.
The listed molecular formula is C10H21NO4.
The listed molecular weight is 219.28 g/mol.
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol.
The source lists Butyldeoxynojirimycin, Zavesca and Yargesa.